Core Viewpoint - Pharmaceutical stocks are under pressure following the announcement of new tariffs on imported pharmaceutical products by U.S. President Trump, which could significantly impact the industry [1] Group 1: Stock Performance - Companies such as 科济药业-B (02171) saw a decline of 5.11%, trading at 18.37 HKD [1] - 康宁杰瑞制药-B (09966) dropped by 3.48%, with a trading price of 12.22 HKD [1] - 维亚生物 (01873) fell by 3.52%, now priced at 2.47 HKD [1] - 泰格医药 (300347) (03347) decreased by 3.1%, trading at 45.6 HKD [1] Group 2: Tariff Announcement - Starting October 1, the U.S. will impose a 100% tariff on all brands and patented pharmaceutical products [1] - Trump indicated that these tariffs will not apply to companies that build factories in the U.S., defining such facilities as "under construction" [1] Group 3: Policy Context - Trump's administration has focused on "lowering drug prices" and "supply chain repatriation" as key themes in its policies affecting the pharmaceutical industry this year [1]

Group 1 - Pharmaceutical stocks are under pressure, with notable declines: 科济药业-B down 5.11% to 18.37 HKD, 康宁杰瑞制药-B down 3.48% to 12.22 HKD, 维亚生物 down 3.52% to 2.47 HKD, and 泰格医药 down 3.1% to 45.6 HKD [1] - On September 25, President Trump announced a new round of high tariffs on various imported products, including a 100% tariff on all brands and patented pharmaceutical products starting October 1 [1] - The tariffs will not apply to companies that build factories in the U.S., defined by Trump as "under construction" [1] Group 2 - Trump's policies this year have focused on the pharmaceutical industry, with key themes being "lower drug prices" and "supply chain repatriation" [1]